Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-119 in advanced solid tumors
NCT02448589Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Sep 2014
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of TAS-119 in solid tumor (advanced stage), sponsored by Taiho Oncology. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 up to 2.5 Years. Started Sep 2014; status: terminated.
02
Drugs
TAS-119
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02448589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448589.